Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2007

01.12.2007 | Educational Review

Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma—A Strategy to Increase Resectability

verfasst von: Wan Yee Lau, MD, FACS, FRCS, FRACS(Hon), Eric C. H. Lai, MB ChB, MRCSEd, FRACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Surgical resection with complete extirpation of the tumor gives the best chance of a cure for patients with hepatocellular carcinoma (HCC). However, the resectability of HCC at the time of diagnosis is low (10–30%). This article reviews the use of salvage surgery following tumor downstaging to treat unresectable HCC.

Materials and Methods

A Medline search was undertaken from 1966 to 2005 to identify articles using the keywords “liver neoplasm,” “hepatocellular carcinoma,” “tumor downstaging,” and “unresectable.” Additional papers were identified by a manual search of the references from the key articles.

Results

Eight to eighteen percent of patients with unresectable HCC responded well enough to the initial palliative treatment to downstage HCC to allow salvage surgical resection. The reported five-year survival rate after salvage surgery following tumor downstaging varied from 24.9 to 57%.

Conclusions

Although it is still unknown whether the outcome of salvage surgery following tumor downstaging is comparable to those of resectable tumors after primary resection, one clear message is that salvage surgery following tumor downstaging gives good long-term results and the possibility of a cure in a proportion of patients with unresectable HCC. The role of salvage surgery after tumor downstaging in improving disease-free and overall survival in patients with unresectable HCC should be investigated further by prospective randomized controlled trials.
Literatur
1.
Zurück zum Zitat Lau WY. Primary hepatocellular carcinoma. In: Blumgart LH, Fong Y, (eds.) Surgery of the Liver and Biliary Tract. 3rd ed. London: WB Saunders, 2000:1423–50 Lau WY. Primary hepatocellular carcinoma. In: Blumgart LH, Fong Y, (eds.) Surgery of the Liver and Biliary Tract. 3rd ed. London: WB Saunders, 2000:1423–50
2.
Zurück zum Zitat Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47:389–99PubMed Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002;47:389–99PubMed
3.
4.
5.
Zurück zum Zitat Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421–7PubMedCrossRef Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94:421–7PubMedCrossRef
6.
Zurück zum Zitat Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–81PubMed Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676–81PubMed
7.
Zurück zum Zitat Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474–84PubMedCrossRef Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474–84PubMedCrossRef
8.
Zurück zum Zitat Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–42PubMedCrossRef Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429–42PubMedCrossRef
9.
Zurück zum Zitat Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres. Int J Radiat Oncol Bio Phys 1998;40:583–92CrossRef Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90 yttrium microspheres. Int J Radiat Oncol Bio Phys 1998;40:583–92CrossRef
10.
Zurück zum Zitat Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236–41PubMedCrossRef Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg 2001; 233:236–41PubMedCrossRef
11.
Zurück zum Zitat Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma. Chinese-Ger J Clin Oncol 2004;3:130–1 Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma. Chinese-Ger J Clin Oncol 2004;3:130–1
13.
Zurück zum Zitat Pierro A, Langevin AM, Filler RM, et al. Preoperative chemotherapy in ‘unresectable’ hepatoblastoma. J Pediatr Surg 1989;24:24–8PubMedCrossRef Pierro A, Langevin AM, Filler RM, et al. Preoperative chemotherapy in ‘unresectable’ hepatoblastoma. J Pediatr Surg 1989;24:24–8PubMedCrossRef
14.
Zurück zum Zitat Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg 1995;19:814–6PubMedCrossRef Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg 1995;19:814–6PubMedCrossRef
15.
Zurück zum Zitat Stringer MD, Hennayake S, Howard ER, et al. Improved outcome for children with hepatoblastoma. Br J Surg 1995;82:386–91PubMedCrossRef Stringer MD, Hennayake S, Howard ER, et al. Improved outcome for children with hepatoblastoma. Br J Surg 1995;82:386–91PubMedCrossRef
16.
Zurück zum Zitat Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002;94:1111–20PubMedCrossRef Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002;94:1111–20PubMedCrossRef
17.
Zurück zum Zitat Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000;89:1845–53PubMedCrossRef Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000;89:1845–53PubMedCrossRef
18.
Zurück zum Zitat Perilongo G, Shafford E, Maibach R, et al. International Society of Paediatric Oncology-SIOPEL 2. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur J Cancer 2004;40:411–21PubMedCrossRef Perilongo G, Shafford E, Maibach R, et al. International Society of Paediatric Oncology-SIOPEL 2. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur J Cancer 2004;40:411–21PubMedCrossRef
19.
Zurück zum Zitat Fuchs J, Rydzynski J, Hecker H, et al. German Cooperative Liver Tumor Studies HB 89 and HB 94. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma–a report from the German Cooperative Liver Tumor Studies HB 89 and HB 94. Eur J Pediatr Surg 2002;12:255–61PubMedCrossRef Fuchs J, Rydzynski J, Hecker H, et al. German Cooperative Liver Tumor Studies HB 89 and HB 94. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma–a report from the German Cooperative Liver Tumor Studies HB 89 and HB 94. Eur J Pediatr Surg 2002;12:255–61PubMedCrossRef
20.
Zurück zum Zitat Fuchs J, Rydzynski J, von Schweinitz D, et al. Study Committee of the Cooperative Pediatric Liver Tumor Study HB 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;95:172–82PubMedCrossRef Fuchs J, Rydzynski J, von Schweinitz D, et al. Study Committee of the Cooperative Pediatric Liver Tumor Study HB 94 for the German Society for Pediatric Oncology and Hematology. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;95:172–82PubMedCrossRef
21.
Zurück zum Zitat von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumor Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997;33:1243–9CrossRef von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumor Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer 1997;33:1243–9CrossRef
22.
Zurück zum Zitat Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003;20:481–96PubMedCrossRef Fusai G, Davidson BR. Strategies to increase the resectability of liver metastases from colorectal cancer. Dig Surg 2003;20:481–96PubMedCrossRef
23.
Zurück zum Zitat Fusai G, Davidson BR. Management of colorectal liver metastases. Colorectal Dis 2003;5:2–23PubMedCrossRef Fusai G, Davidson BR. Management of colorectal liver metastases. Colorectal Dis 2003;5:2–23PubMedCrossRef
24.
Zurück zum Zitat Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–20PubMedCrossRef Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509–20PubMedCrossRef
25.
Zurück zum Zitat Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–9PubMedCrossRef Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004;15:933–9PubMedCrossRef
26.
Zurück zum Zitat Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57PubMedCrossRef Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644–57PubMedCrossRef
27.
Zurück zum Zitat Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer 1978;42:336–48PubMedCrossRef Stocker JT, Ishak KG. Undifferentiated (embryonal) sarcoma of the liver: report of 31 cases. Cancer 1978;42:336–48PubMedCrossRef
28.
Zurück zum Zitat Horowitz ME, Etcubanas E, Webber BL, et al. Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer 1987;59:396–402PubMedCrossRef Horowitz ME, Etcubanas E, Webber BL, et al. Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer 1987;59:396–402PubMedCrossRef
29.
Zurück zum Zitat Urban CE, Mache CJ, Schwinger W, et al. Undifferentiated (embryonal) sarcoma of the liver in childhood. Successful combined-modality therapy in four patients. Cancer 1993;72:2511–6PubMedCrossRef Urban CE, Mache CJ, Schwinger W, et al. Undifferentiated (embryonal) sarcoma of the liver in childhood. Successful combined-modality therapy in four patients. Cancer 1993;72:2511–6PubMedCrossRef
30.
Zurück zum Zitat Bisogno G, Pilz T, Perilongo G, et al. Undifferentiated sarcoma of the liver in childhood: a curable disease. Cancer 2002;94:252–7PubMedCrossRef Bisogno G, Pilz T, Perilongo G, et al. Undifferentiated sarcoma of the liver in childhood: a curable disease. Cancer 2002;94:252–7PubMedCrossRef
31.
Zurück zum Zitat Kim DY, Kim KH, Jung SE, et al. Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. J Pediatr Surg 2002;37:1419–23PubMedCrossRef Kim DY, Kim KH, Jung SE, et al. Undifferentiated (embryonal) sarcoma of the liver: combination treatment by surgery and chemotherapy. J Pediatr Surg 2002;37:1419–23PubMedCrossRef
32.
Zurück zum Zitat Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610–30PubMed Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610–30PubMed
33.
Zurück zum Zitat Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–66PubMedCrossRef
34.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18PubMedCrossRef Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309–18PubMedCrossRef
35.
Zurück zum Zitat Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71PubMedCrossRef Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59–71PubMedCrossRef
36.
Zurück zum Zitat Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476–87PubMedCrossRef Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476–87PubMedCrossRef
37.
Zurück zum Zitat Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–47PubMed Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–47PubMed
38.
Zurück zum Zitat de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47PubMed de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47PubMed
39.
Zurück zum Zitat Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14CrossRef Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905–14CrossRef
40.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicener randomised trial. Lancet 2000;355:1041–7PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicener randomised trial. Lancet 2000;355:1041–7PubMedCrossRef
41.
Zurück zum Zitat Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998;15:674–8PubMedCrossRef Fan J, Tang ZY, Yu YQ, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 1998;15:674–8PubMedCrossRef
42.
Zurück zum Zitat Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701PubMedCrossRef Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701PubMedCrossRef
43.
Zurück zum Zitat Tang ZY, Zhou XD, Ma ZC, et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3:495–8PubMed Tang ZY, Zhou XD, Ma ZC, et al. Downstaging followed by resection plays a role in improving prognosis of unresectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2004;3:495–8PubMed
44.
Zurück zum Zitat Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004;240:299–305PubMedCrossRef Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 2004;240:299–305PubMedCrossRef
45.
Zurück zum Zitat Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993; 217:149–54PubMed Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg 1993; 217:149–54PubMed
46.
Zurück zum Zitat Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000;7:490–5PubMedCrossRef Meric F, Patt YZ, Curley SA, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol 2000;7:490–5PubMedCrossRef
47.
Zurück zum Zitat Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002;131:433–42PubMedCrossRef Clavien PA, Selzner N, Morse M, et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002;131:433–42PubMedCrossRef
48.
Zurück zum Zitat Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532–8PubMedCrossRef Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532–8PubMedCrossRef
Metadaten
Titel
Salvage Surgery Following Downstaging of Unresectable Hepatocellular Carcinoma—A Strategy to Increase Resectability
verfasst von
Wan Yee Lau, MD, FACS, FRCS, FRACS(Hon)
Eric C. H. Lai, MB ChB, MRCSEd, FRACS
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9549-7

Weitere Artikel der Ausgabe 12/2007

Annals of Surgical Oncology 12/2007 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.